Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IO Biotech, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PRE-CLINICAL DATA FOR IO BIOTECH'S NEXT T-WIN VACCINE CANDIDATE, IO112 TARGETING ARGINASE 1, DEMONSTRATES ANTI-TUMOR ACTIVITY WITH DYNAMIC CHANGES IN THE TUMOR MICROENVIRONMENT (TME) DRIVEN BY THE VACCINE-TARGETED MODULATION OF IMMUNOSUPPRESSIVE MYELOID CELLS, INCLUDING TUMOR-ASSOCIATED MACROPHAGES (TAMS) PRE-CLINICAL DATA FOR IO BIOTECH'S ADDITIONAL T-WIN VACCINE CANDIDATE, IO170 TARGETING TRANSFORMING GROWTH FACTOR (TGF)-, DEMONSTRATES INDUCTION OF IMMUNE RESPONSES THAT COULD INHIBIT TUMOR GROWTH AND REDUCE LUNG METASTASIS DATA PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S ANNUAL MEETING NEW YORK, NOV. 07, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY ANNOUNCED NEW PRE-CLINICAL DATA FOR IO BIOTECH'S NEXT VACCINE CANDIDATE, IO112, AND ADDITIONAL CANDIDATE, IO170, WILL BE PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S 40TH ANNUAL MEETING (SITC 2025) IN MARYLAND ON NOVEMBER 5-9, 2025. THIS NEW DATA IS EXTREMELY IMPORTANT FOR OUR DEVELOPMENT PATH AS IT POINTS TOWARD MORE POTENTIAL INDICATIONS FOR OUR NOVEL, IMMUNE-MODULATORY THERAPEUTIC VACCINES TO TREAT PATIENTS WITH A RANGE OF CANCERS, SAID MAI-BRITT ZOCCA, PHD, PRESIDENT AND CEO OF IO BIOTECH.

IO BIOTECH PRESENTS PRE-CLINICAL DATA HIGHLIGHTING THE POTENTIAL OF ADDITIONAL THERAPEUTIC CANCER VACCINE CANDIDATES AT THE 2025 ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)

CYLEMBIO PLUS PEMBROLIZUMAB ACHIEVED A CLINICALLY RELEVANT 19.4 MONTHS MEDIAN PROGRESSION FREE SURVIVAL (MPFS) COMPARED TO 11.0 MONTHS MPFS WITH PEMBROLIZUMAB ALONE; STUDY NARROWLY MISSED PROGRESSION FREE SURVIVAL (PFS) PRIMARY ENDPOINT FOR STATISTICAL SIGNIFICANCE IMPROVEMENT IN PFS FAVORED THE COMBINATION ACROSS VIRTUALLY ALL SUBGROUPS, NOTABLY IN PATIENTS WITH PD-L1-NEGATIVE TUMORS, BRAF V600 -MUTATED TUMORS, AND ELEVATED LDH, WITHOUT ADDING ANY SYSTEMIC TOXICITY COMPARED TO PEMBROLIZUMAB ALONE FINAL DATA FROM THE PHASE 2 BASKET TRIAL IN LUNG AND HEAD & NECK CANCERS ALSO PRESENTED NEW YORK, OCT. 20, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY PRESENTED DETAILED RESULTS FROM ITS GLOBAL PHASE 3 TRIAL (IOB-013/KN-D18) OF CYLEMBIO (IMSAPEPIMUT AND ETIMUPEPIMUT, ADJUVANTED), IN COMBINATION WITH MERCK'S (KNOWN AS MSD OUTSIDE THE UNITED STATES AND CANADA) ANTI-PD-1 THERAPY KEYTRUDA (PEMBROLIZUMAB), FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC (ADVANCED) MELANOMA. THE DATA, PRESENTED AS A PROFFERED PAPER AT THE MELANOMA AND OTHER SKIN TUMORS SESSION OF THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS IN BERLIN, EXPAND UPON TOPLINE RESULTS REPORTED IN AUGUST 2025.

IO BIOTECH PRESENTS PHASE 3 RESULTS FOR CYLEMBIO PLUS KEYTRUDA (PEMBROLIZUMAB) IN FIRST-LINE ADVANCED MELANOMA AT ESMO 2025

FDA RECOMMENDS THAT IO BIOTECH NOT SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) BASED ON THE DATA FROM THE IOB-013 CLINICAL TRIAL COMPANY PLANS TO DESIGN NEW REGISTRATIONAL STUDY FOR CYLEMBIO FOR THE TREATMENT OF FIRST-LINE PATIENTS WITH ADVANCED MELANOMA COMPANY IMPLEMENTING A RESTRUCTURING, REDUCING ITS WORKFORCE BY APPROXIMATELY 50 PERCENT NEW YORK, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY PROVIDED AN UPDATE ON THE REGULATORY PATHWAY FOR CYLEMBIO (IMSAPEPIMUT AND ETIMUPEPIMUT, ADJUVANTED) FOLLOWING A PRE-BLA MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA).

IO BIOTECH PROVIDES UPDATE FOLLOWING PRE-BLA MEETING WITH FDA

ORAL PRESENTATION WILL HIGHLIGHT THE RESULTS FROM THE RANDOMIZED PHASE 3 TRIAL (IOB-013/KN-D18) OF IO102-IO103 CANCER VACCINE PLUS PEMBROLIZUMAB FOR FIRST-LINE (1L) ADVANCED MELANOMA POSTER PRESENTATION WILL SHARE FINAL DATA FROM PHASE 2 BASKET TRIAL (IOB-022/KN-D38) OF IO102-IO103 CANCER VACCINE PLUS PEMBROLIZUMAB FOR 1L TREATMENT OF SOLID TUMORS NEW YORK, SEPT. 23, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY ANNOUNCES A LATE-BREAKING ABSTRACT HAS BEEN ACCEPTED AND SELECTED AS A PROFFERED PAPER ORAL PRESENTATION AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS TAKING PLACE IN BERLIN, GERMANY FROM OCTOBER 17-21, 2025.

IO BIOTECH ANNOUNCES LATE-BREAKING ABSTRACT IN ADVANCED MELANOMA SELECTED FOR ORAL PRESENTATION AT ESMO CONGRESS 2025

NEW YORK, SEPT. 04, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, ANNOUNCED TODAY THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PROVIDE A CORPORATE UPDATE AND PARTICIPATE IN ONE-ON-ONE MEETINGS AT THE FOLLOWING UPCOMING INVESTOR CONFERENCES: EVENT: MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCELOCATION: NEW YORK, NEW YORKFIRESIDE CHAT DATE & TIME: TUESDAY, SEPTEMBER 9, 2025 AT 7:45 AM ETPRESENTERS: MAI-BRITT ZOCCA, PHD, PRESIDENT AND CEO, AMY SULLIVAN, CFO, AND QASIM AHMAD, MD, CMOWEBCAST LINK: HERE EVENT: H.C.

IO BIOTECH ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

ANNOUNCED CLINICAL IMPROVEMENT IN PROGRESSION FREE SURVIVAL OBSERVED IN PIVOTAL PHASE 3 TRIAL OF CYLEMBIO PLUS KEYTRUDA (PEMBROLIZUMAB) FOR THE TREATMENT OF FIRST-LINE ADVANCED MELANOMA, BUT STATISTICAL SIGNIFICANCE NARROWLY MISSED; COMPANY PLANS TO MEET WITH FDA THIS FALL TO DISCUSS DATA AND NEXT STEPS FOR A POTENTIAL REGULATORY SUBMISSION ENDED SECOND QUARTER WITH APPROXIMATELY $28.1 MILLION IN CASH AND CASH EQUIVALENTS; THE COMPANY EXPECTS THAT OUR CASH POSITION, TOGETHER WITH 12.5 MILLION IN PROCEEDS FROM THE SECOND TRANCHE OF THE EUROPEAN INVESTMENT BANK (EIB) LOAN FACILITY RECEIVED ON JULY 4, 2025, WILL BE SUFFICIENT TO CONTINUE FUNDING OUR OPERATIONS INTO THE FIRST QUARTER OF 2026 CORPORATE PRESENTATIONS ARE PLANNED FOR THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE ON SEPTEMBER 9, 2025, AND THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE ON SEPTEMBER 10, 2025 NEW YORK, AUG. 14, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE SECOND QUARTER OF 2025.

IO BIOTECH REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS

PATIENTS TREATED WITH CYLEMBIO (IMSAPEPIMUT AND ETIMUPEPIMUT, ADJUVANTED) PLUS PEMBROLIZUMAB ACHIEVED IMPROVEMENT IN PROGRESSION FREE SURVIVAL (PFS) COMPARED TO PATIENTS TREATED WITH PEMBROLIZUMAB MONOTHERAPY, HR=0.77 (CI 0.58-1.00), (P=0.056), WITH MEDIAN PFS (MPFS) OF 19.4 MONTHS VS. 11.0 MONTHS, RESPECTIVELY; THE RESULTS ON THE PRIMARY ENDPOINT NARROWLY MISSED THE STUDY'S STATISTICAL SIGNIFICANCE THRESHOLD OF P0.045 IN PATIENTS ENROLLED IN THIS STUDY WITHOUT PRIOR NEO-ADJUVANT/ADJUVANT ANTI-PD-1 TREATMENT (N=371), PATIENTS TREATED WITH CYLEMBIO PLUS PEMBROLIZUMAB ACHIEVED IMPROVEMENT IN PFS, HR: 0.74 (CI 0.56-0.98) (NOMINAL P=0.037), WITH MPFS OF 24.8 MONTHS VS.

IO BIOTECH ANNOUNCES CLINICAL IMPROVEMENT IN PROGRESSION FREE SURVIVAL DEMONSTRATED IN PIVOTAL PHASE 3 TRIAL OF CYLEMBIO PLUS KEYTRUDA (PEMBROLIZUMAB) FOR THE TREATMENT OF FIRST-LINE ADVANCED MELANOMA, BUT STATISTICAL SIGNIFICANCE NARROWLY MISSED

NEW YORK, AUG. 10, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE COMPANY WILL HOLD A CONFERENCE CALL AND WEBCAST ON MONDAY, AUGUST 11, 2025, AT 8:30 AM ET TO DISCLOSE THE TOPLINE RESULTS OF THE PIVOTAL PHASE 3 TRIAL (IOB-013/KN-D18; NCT05155254) OF ITS INVESTIGATIONAL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINE, CYLEMBIO (IMSAPEPIMUT AND ETIMUPEPIMUT, ADJUVANT) IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS A FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC (ADVANCED) MELANOMA.

IO BIOTECH TO ANNOUNCE TOPLINE RESULTS OF PIVOTAL PHASE 3 TRIAL OF CYLEMBIO IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) AS A FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA

NEW YORK, MAY 20, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, ANNOUNCED TODAY THAT MAI-BRITT ZOCCA, PHD, THE COMPANY'S PRESIDENT AND CEO, ALONG WITH AMY SULLIVAN, THE COMPANY'S CFO, AND QASIM AHMAD, MD, THE COMPANY'S CMO, WILL BE PARTICIPATING IN A FIRESIDE CHAT AT THE TD COWEN 6TH ANNUAL ONCOLOGY SUMMIT: INSIGHTS FOR ASCO & EHA BEING HELD VIRTUALLY MAY 27-28, 2025. ADDITIONALLY, DR. ZOCCA WILL BE PRESENTING AND DR. ZOCCA, AMY SULLIVAN, AND DR. AHMAD WILL BE PARTICIPATING IN ONE-ON-ONE INVESTOR MEETINGS AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE TO BE HELD JUNE 3-5, 2025 IN NEW YORK, NY.

IO BIOTECH ANNOUNCES PARTICIPATION IN COWEN 6TH ANNUAL ONCOLOGY INNOVATION SUMMIT AND JEFFERIES GLOBAL HEALTHCARE CONFERENCE

PRIMARY ENDPOINT OF PIVOTAL PHASE 3 TRIAL (IOB-013/KN-D18) OF LEAD INVESTIGATIONAL THERAPEUTIC CANCER VACCINE IN PATIENTS WITH ADVANCED MELANOMA STILL EXPECTED TO READOUT IN THIRD QUARTER OF 2025 DATA PRESENTED AT RECENT CONGRESSES REINFORCES THE POTENTIAL OF THE COMPANY'S T-WIN CANDIDATES TO RESHAPE THE TUMOR MICROENVIRONMENT AND DRIVE MORE EFFECTIVE ANTI-TUMOR RESPONSES COMPANY RECOGNIZED AS ONE OF THE MOST INNOVATIVE BIOTECHNOLOGY COMPANIES IN THE WORLD BY FAST COMPANY COMPANY TO PARTICIPATE IN TD COWEN'S 6TH ANNUAL ONCOLOGY INNOVATION SUMMIT ON MAY 27 AND JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON JUNE 4, 2025 NEW YORK, MAY 14, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE FIRST QUARTER OF 2025. THE COMPANY CONTINUES TO ADVANCE ITS PIPELINE, PRESENTING NEW DATA FURTHER DEFINING THE MECHANISM OF ACTION FOR ITS T-WIN THERAPEUTIC CANCER VACCINES, AND REAFFIRMING ITS EXPECTATION THAT THE PHASE 3 PIVOTAL TRIAL WILL READOUT IN THE THIRD QUARTER OF 2025.

IO BIOTECH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

NEW YORK, APRIL 26, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY ANNOUNCED THAT ONE OF ITS SCIENTIFIC CO-FOUNDERS, MADS HALD ANDERSEN, DMSC, PHD, DIRECTOR OF THE NATIONAL CENTER FOR CANCER IMMUNE THERAPY (CCIT-DK), CHAIRED AND PRESENTED AT AN EDUCATIONAL SESSION ON CANCER VACCINES AT THE 2025 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING. THE SESSION BROUGHT TOGETHER LEADING ONCOLOGY SCIENTISTS AND EXPLORED THE LATEST ADVANCEMENTS IN CANCER VACCINE RESEARCH, FROM PRECLINICAL INNOVATION TO CLINICAL IMPLEMENTATION, PROVIDING PERSPECTIVE ON THE FUTURE OF CANCER VACCINES AND THEIR POTENTIAL TO RESHAPE CANCER IMMUNOTHERAPY (SESSION #ED59).

IO BIOTECH SHOWCASES SCIENTIFIC LEADERSHIP THROUGH CANCER VACCINES EDUCATIONAL SESSION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025

IO Biotech, Inc.

IOBT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IO Biotech, Inc.

IOBT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IOBT